Literature DB >> 17243491

Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.

Gerd Schmitz1.   

Abstract

OncoGenex Technologies Inc in collaboration with Isis Pharmaceuticals Inc is developing OGX-011, an intravenously administered clusterin-inhibiting antisense oligonucleotide, to potentially sensitize solid tumors that are resistant to conventional cancer therapeutics. Phase II clinical trials of OGX-011 in combination with chemotherapeutic drugs are underway in NSCLC, prostate and breast cancer.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17243491

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  4 in total

1.  A signaling network in phenylephrine-induced benign prostatic hyperplasia.

Authors:  Jayoung Kim; Yutaka Yanagihara; Tadahiko Kikugawa; Mihee Ji; Nozomu Tanji; Yokoyama Masayoshi; Michael R Freeman
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

2.  Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.

Authors:  Olesya Chayka; Daisy Corvetta; Michael Dews; Alessandro E Caccamo; Izabela Piotrowska; Giorgia Santilli; Sian Gibson; Neil J Sebire; Nourredine Himoudi; Michael D Hogarty; John Anderson; Saverio Bettuzzi; Andrei Thomas-Tikhonenko; Arturo Sala
Journal:  J Natl Cancer Inst       Date:  2009-04-28       Impact factor: 13.506

3.  siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival.

Authors:  Gang Zeng; Udayan Apte; Benjamin Cieply; Sucha Singh; Satdarshan P S Monga
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

4.  Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker.

Authors:  Adriana Aguilar-Mahecha; Christiane Cantin; Maureen O'Connor-McCourt; Andre Nantel; Mark Basik
Journal:  Proteome Sci       Date:  2009-04-06       Impact factor: 2.480
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.